Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.

Bristol-Myers Squibb will deploy Sirenas’ drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug candidates.